Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model

Acta Dermato-Venereologica

Volumn 94, Issue 6, 2014, Pages 672-676

  Stenderup, Karin ^a   Rosada, Cecilia ^a   Gavillet, Bruno ^b   Vuagniaux, Grégoire ^b   Dam, Tomas Norman ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DEBIOPHARM SA   (Switzerland)

^c ROSKILDE HOSPITAL   (Denmark)

Author keywords

Hsp90; Psoriasis; Xenograft model

Indexed keywords

DEBIO 0932; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; CUDC 305; DERMATOLOGICAL AGENT; IMIDAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHEMA; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PSORIASIS; SIGNAL TRANSDUCTION; SKINFOLD THICKNESS; TREATMENT DURATION; VASCULARIZATION; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; FEMALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; REMISSION; SCID MOUSE; SKIN; SKIN TRANSPLANTATION; TIME; XENOGRAFT;

ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; BENZODIOXOLES; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; MICE, SCID; MIDDLE AGED; PSORIASIS; REMISSION INDUCTION; SIGNAL TRANSDUCTION; SKIN; SKIN TRANSPLANTATION; TIME FACTORS;

EID: 84907998268     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1838     Document Type: Article

References (32)

1. Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009; 15: 4046-4057.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
3. Tonel G, Conrad C. Interplay between keratinocytes and immune cells - recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 2009; 41: 963-968.
4. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
5. Gulliver WP, Macdonald D, Gladney N, Alaghehbandan R, Rahman P, Adam Baker K. Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. J Cutan Med Surg 2011; 15: 37-47.
6. Edwards MJ, Marks R, Dykes PJ, Merrett VR, Morgan HE, O'Donovan MR. Heat shock proteins in cultured human keratinocytes and fibroblasts. J Invest Dermatol 1991; 96: 392-396.
7. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 2013; 39: 375-387.
8. Dou F, Yuan LD, Zhu JJ. Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism. Acta Biochim Biophys Sin 2005; 37: 501-505.
9. Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012; 209: 259-273.
10. Wang C, Wu L, Bulek K, Martin BN, Zepp JA, Kang Z, et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013; 14: 72-81.
11. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-313.
12. Boyman O, Conrad C, Dudli C, Kielhorn E, Nickoloff BJ, Nestle FO. Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br J Dermatol 2005; 152: 1211-1218.
13. Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, et al. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem 2006; 99: 1351-1362.
14. Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, Antonova G, Snead C, Cannon J, et al. Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med 2007; 176: 667-675.
15. Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, et al. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 2008; 58: 3765-3775.
16. Yun TJ, Harning EK, Giza K, Rabah D, Li P, Arndt JW, et al. EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J Immunol 2011; 186: 563-575.
17. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ. 1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 1999; 113: 1082-1089.
18. Stenderup K, Rosada C, Dam TN, Salerno E, Belinka BA, Kachlany SC. Resolution of psoriasis by a leukocytetargeting bacterial protein in a humanized mouse model. J Invest Dermatol 2011; 131: 2033-2039.
19. Stenderup K, Rosada C, Worsaae A, Dagnaes-Hansen F, Steiniche T, Hasselager E, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009; 160: 284-296.
20. Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacoly 2012; 65: 471-517.
21. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 2010; 6: 704-714.
22. Petersen TK, Sorensen P. Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies. Drug Discov Today 2008; 13: 240-246.
23. Stenderup K, Rosada C, Alifrangis L, Andersen S, Dam TN. Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A. Exp Dermatol 2011; 20: 441-444.
24. Boniface K, Blom B, Liu YJ, de Waal MR. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008; 226: 132-146.
25. Shi L, Zhang Z, Fang S, Xu J, Liu J, Shen J, et al. Heat shock protein 90 (Hsp90) regulates the stability of transforming growth factor beta-activated kinase 1 (TAK1) in interleukin-1beta-induced cell signaling. Mol Immunol 2009; 46: 541-550.
26. Shang L, Tomasi TB. The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J Biol Chem 2006; 281: 1876-1884.
27. Howard M, Roux J, Iles KE, Miyazawa B, Christiaans S, Anjum N, et al. Activation of the heat shock response attenuates the interleukin 1beta-mediated inhibition of the amiloride-sensitive alveolar epithelial ion transport. Shock 2013; 39: 189-196.
28. Sato N, Yamamoto T, Sekine Y, Yumioka T, Junicho A, Fuse H, et al. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem Biophys Res Commun 2003; 300: 847-852.
29. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, Kuban RJ, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007; 109: 720-728.
30. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEKmitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996; 16: 5839-5845.
31. Jaiswal RK, Weissinger E, Kolch W, Landreth GE. Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J Biol Chem 1996; 271: 23626-23629.
32. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 2000; 275: 10519-10526.